niacinamide has been researched along with Cardiovascular Diseases in 32 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
Cardiovascular Diseases: Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Other adverse events, dosing and outcome data were collected during a homogeneous protocolled follow-up." | 5.62 | Evaluation of cardiovascular events in patients with hepatocellular carcinoma treated with sorafenib in the clinical practice. The CARDIO-SOR study. ( Álvarez-Navascués, C; Álvarez-Velasco, R; Cadahía, V; Carballo-Folgoso, L; Castaño-García, A; Cuevas, J; González-Diéguez, ML; Lorca, R; Martín, M; Morís, C; Rodríguez, M; Varela, M, 2021) |
| "The purpose of the present study was to determine the relationship between iatrogenic arterial hypertension or baseline cardiovascular comorbidities and outcomes in metastatic renal cell cancer (mRCC) patients treated with sorafenib." | 3.78 | Cardiovascular comorbidities for prediction of progression-free survival in patients with metastatic renal cell carcinoma treated with sorafenib. ( Filipiak, KJ; Nurzyński, P; Opolski, G; Szczylik, C; Szmit, S; Waśko-Grabowska, A; Zaborowska, M; Żołnierek, J, 2012) |
| "Sorafenib was well tolerated in both subgroups (grade 3/4: 20 and 22%, respectively)." | 2.75 | Efficacy and safety of sorafenib in patients with advanced renal cell carcinoma with and without prior cytokine therapy, a subanalysis of TARGET. ( Anderson, S; Bellmunt, J; Bukowski, R; Cihon, F; Escudier, B; Jäger, E; Lewis, J; McDermott, D; Moore, M; Negrier, S; Porta, C, 2010) |
| "The treatment of rheumatoid arthritis has changed dramatically over the last two decades since the development of biological disease-modifying anti-rheumatic drugs (bDMARDs)." | 2.66 | JAK inhibitors for the treatment of rheumatoid arthritis. ( Morinobu, A, 2020) |
| "Treatment of breast cancer (BC) has changed over the last decade with the advent of targeted therapies." | 2.47 | Predicting and preventing cardiotoxicity in the era of breast cancer targeted therapies. Novel molecular tools for clinical issues. ( Catalano, O; De Giuli, L; Della Porta, MG; Eleuteri, E; Riccardi, A; Tondini, C; Zambelli, A, 2011) |
| " Strict monitoring of treatment-related adverse effects must be conducted in order to allow the early detection of cardiovascular toxicities and their prompt medication." | 2.46 | Cardiovascular safety of VEGF-targeting therapies: current evidence and handling strategies. ( Brandes, AA; Franceschi, E; Girardi, F, 2010) |
| " With expanded clinical experience with this class of agents has come the increasing recognition of the diverse adverse effects related to disturbance of VEGF-dependent physiological functions and homeostasis in the cardiovascular and renal systems, as well as wound healing and tissue repair." | 2.45 | Adverse effects of anticancer agents that target the VEGF pathway. ( Chen, HX; Cleck, JN, 2009) |
| " Other adverse events, dosing and outcome data were collected during a homogeneous protocolled follow-up." | 1.62 | Evaluation of cardiovascular events in patients with hepatocellular carcinoma treated with sorafenib in the clinical practice. The CARDIO-SOR study. ( Álvarez-Navascués, C; Álvarez-Velasco, R; Cadahía, V; Carballo-Folgoso, L; Castaño-García, A; Cuevas, J; González-Diéguez, ML; Lorca, R; Martín, M; Morís, C; Rodríguez, M; Varela, M, 2021) |
| " The incidence of cardiovascular adverse events, including congestive heart failure and cardiomyopathy (CHF/CM), acute myocardial infarction (AMI), stroke, and cardiovascular deaths, was examined through December 2010." | 1.43 | Cardiovascular toxicity after antiangiogenic therapy in persons older than 65 years with advanced renal cell carcinoma. ( Atkins, MB; Barac, A; Freedman, AN; Fu, AZ; Jang, S; Minasian, L; Potosky, AL; Tsai, HT; Zheng, C, 2016) |
| "Treatment with small molecule tyrosine kinase inhibitors (TKIs) has improved survival in many cancers, yet has been associated with an increased risk of adverse events." | 1.42 | Cardiovascular toxicity of multi-tyrosine kinase inhibitors in advanced solid tumors: a population-based observational study. ( Amir, E; Ethier, JL; Krzyzanowska, MK; Ocana, A; Seruga, B; Srikanthan, A, 2015) |
| "Hyperphosphatemia is thought to be a central-risk factor for CKD-MBD." | 1.42 | Niacin and Chronic Kidney Disease. ( Masuda, M; Miyamoto, K; Segawa, H; Takeda, E; Taketani, Y; Tatsumi, S; Yamamoto, H; Yamanaka-Okumura, H, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (12.50) | 18.7374 |
| 1990's | 3 (9.38) | 18.2507 |
| 2000's | 5 (15.63) | 29.6817 |
| 2010's | 16 (50.00) | 24.3611 |
| 2020's | 4 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Davies, SG | 1 |
| Kennewell, PD | 1 |
| Russell, AJ | 1 |
| Seden, PT | 1 |
| Westwood, R | 1 |
| Wynne, GM | 1 |
| Nejabati, HR | 1 |
| Samadi, N | 1 |
| Roshangar, L | 1 |
| Nouri, M | 1 |
| Mehmel, M | 1 |
| Jovanović, N | 1 |
| Spitz, U | 1 |
| Morinobu, A | 1 |
| Carballo-Folgoso, L | 1 |
| Álvarez-Velasco, R | 1 |
| Lorca, R | 1 |
| Castaño-García, A | 1 |
| Cuevas, J | 1 |
| González-Diéguez, ML | 1 |
| Martín, M | 1 |
| Álvarez-Navascués, C | 1 |
| Cadahía, V | 1 |
| Morís, C | 1 |
| Rodríguez, M | 1 |
| Varela, M | 2 |
| Abdellatif, M | 1 |
| Baur, JA | 1 |
| Levy, A | 1 |
| Menard, J | 1 |
| Albiges, L | 1 |
| Loriot, Y | 1 |
| Di Palma, M | 1 |
| Fizazi, K | 1 |
| Escudier, B | 2 |
| Abdel-Rahman, O | 1 |
| Fouad, M | 1 |
| Srikanthan, A | 1 |
| Ethier, JL | 1 |
| Ocana, A | 1 |
| Seruga, B | 1 |
| Krzyzanowska, MK | 1 |
| Amir, E | 1 |
| Haas, NB | 1 |
| Manola, J | 1 |
| Ky, B | 1 |
| Flaherty, KT | 1 |
| Uzzo, RG | 1 |
| Kane, CJ | 1 |
| Jewett, M | 1 |
| Wood, L | 1 |
| Wood, CG | 1 |
| Atkins, MB | 2 |
| Dutcher, JJ | 1 |
| Wilding, G | 1 |
| DiPaola, RS | 1 |
| Jang, S | 1 |
| Zheng, C | 1 |
| Tsai, HT | 1 |
| Fu, AZ | 1 |
| Barac, A | 1 |
| Freedman, AN | 1 |
| Minasian, L | 1 |
| Potosky, AL | 1 |
| Fenner, A | 1 |
| Taketani, Y | 1 |
| Masuda, M | 1 |
| Yamanaka-Okumura, H | 1 |
| Tatsumi, S | 1 |
| Segawa, H | 1 |
| Miyamoto, K | 1 |
| Takeda, E | 1 |
| Yamamoto, H | 1 |
| Lenihan, DJ | 1 |
| Schmidinger, M | 1 |
| Zielinski, CC | 1 |
| Vogl, UM | 1 |
| Bojic, A | 1 |
| Bojic, M | 1 |
| Schukro, C | 1 |
| Ruhsam, M | 1 |
| Hejna, M | 1 |
| Schmidinger, H | 1 |
| Chen, HX | 1 |
| Cleck, JN | 1 |
| Negrier, S | 1 |
| Jäger, E | 1 |
| Porta, C | 1 |
| McDermott, D | 1 |
| Moore, M | 1 |
| Bellmunt, J | 1 |
| Anderson, S | 1 |
| Cihon, F | 1 |
| Lewis, J | 1 |
| Bukowski, R | 1 |
| Vaklavas, C | 1 |
| Lenihan, D | 1 |
| Kurzrock, R | 1 |
| Tsimberidou, AM | 1 |
| Girardi, F | 1 |
| Franceschi, E | 1 |
| Brandes, AA | 1 |
| Reig, M | 1 |
| Matilla, A | 1 |
| Bustamante, J | 1 |
| Castells, L | 1 |
| de La Mata, M | 1 |
| Delgado, M | 1 |
| Moreno, JM | 1 |
| Forner, A | 1 |
| Zambelli, A | 1 |
| Della Porta, MG | 1 |
| Eleuteri, E | 1 |
| De Giuli, L | 1 |
| Catalano, O | 1 |
| Tondini, C | 1 |
| Riccardi, A | 1 |
| Sacco, R | 1 |
| Bargellini, I | 1 |
| Ginanni, B | 1 |
| Bertini, M | 1 |
| Bozzi, E | 1 |
| Altomare, E | 1 |
| Battaglia, V | 1 |
| Romano, A | 1 |
| Tumino, E | 1 |
| Di Biase, M | 1 |
| Bresci, G | 1 |
| Bartolozzi, C | 1 |
| Szmit, S | 1 |
| Zaborowska, M | 1 |
| Waśko-Grabowska, A | 1 |
| Żołnierek, J | 1 |
| Nurzyński, P | 1 |
| Filipiak, KJ | 1 |
| Opolski, G | 1 |
| Szczylik, C | 1 |
| KLEIN, HG | 1 |
| Bover, J | 1 |
| Ortiz-Herbener, F | 1 |
| Ballarín, J | 1 |
| Andrés, E | 1 |
| Barceló, P | 1 |
| Mego, M | 1 |
| Reckova, M | 1 |
| Obertova, J | 1 |
| Sycova-Mila, Z | 1 |
| Brozmanova, K | 1 |
| Mardiak, J | 1 |
| Utoh, J | 1 |
| Miyauchi, Y | 1 |
| Goto, H | 1 |
| Obayashi, H | 1 |
| Hirata, T | 1 |
| Atwal, KS | 1 |
| Quast, U | 1 |
| Severin, SE | 1 |
| Pietranera, P | 1 |
| Dal Ri, L | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Nicotinamide Riboside in Ulcerative Colitis[NCT05561738] | 40 participants (Anticipated) | Interventional | 2024-01-01 | Not yet recruiting | |||
| A Phase III Randomized Study of BAY43-9006 in Patients With Unresectable and/or Metastatic Renal Cell Cancer.[NCT00073307] | Phase 3 | 903 participants (Actual) | Interventional | 2003-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Overall survival determined as the time (days) from the date of randomization at start of study to the date of death, due to any cause. Outcome measure was assessed regularly, i.e. every 3 weeks for the first 24 weeks during treatment and every 4 weeks thereafter and approximately every 3 months during post-treatment. (NCT00073307)
Timeframe: From start of randomization of the first subject (1Dec2003) until the data cut-off (8Sep2006) for the final OS analysis, approximately 33 months later
| Intervention | days (Median) |
|---|---|
| Sorafenib (Nexavar, BAY43-9006) | 542 |
| Placebo | 436 |
Overall survival determined as the time (days) from the date of randomization at start of study to the date of death, due to any cause. Outcome measure was assessed regularly, i.e. every 3 weeks for the first 24 weeks during treatment and every 4 weeks thereafter and approximately every 3 months during post-treatment. (NCT00073307)
Timeframe: From start of randomization of the first subject (1Dec2003) until the data cut-off (8Sep2006) for the final OS analysis, approximately 33 months later
| Intervention | days (Median) |
|---|---|
| Sorafenib (Nexavar, BAY43-9006) | 542 |
| Placebo | 461 |
PFS determined as the time (days) from the date of randomization at start of study to the actual date of disease progression (PD) (radiological or clinical) or death due to any cause, if death occurred before PD. Outcome measure was assessed approximately every 8 weeks using RECIST v1.0 criteria by independent radiologic review. Radiological PD defined as at least 20% increase in sum of longest diameter (LD) of measured lesions taking as reference smallest sum LD recorded since treatment started or appearance of new lesions. (NCT00073307)
Timeframe: From start of randomization of the first subject (1Dec2003) until the data cut-off (28Jan2005), approximately 14 months later, tumors assessed every 8 weeks.
| Intervention | days (Median) |
|---|---|
| Sorafenib (Nexavar, BAY43-9006) | 167 |
| Placebo | 84 |
Best overall response was determined according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.0 by independent radiologic review. Categories: complete response (CR, tumor disappears), partial response (PR, sum of lesion sizes decreased), stable disease (SD, steady state of disease), progressive disease (PD, sum of lesion sizes increased) and not evaluated. (NCT00073307)
Timeframe: From start of randomization of the first subject (1Dec2003) until the data cut-off (28Jan2005), approximately 14 months later, tumors assessed every 8 weeks.
| Intervention | percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Complete Response | Partial Response | Stable Disease | Progressive Disease | Not Evaluated | |
| Placebo | 0.0 | 0.0 | 55.2 | 30.3 | 14.5 |
| Sorafenib (Nexavar, BAY43-9006) | 0.0 | 2.1 | 77.9 | 8.7 | 11.3 |
"Primary Analysis for FKSI-10 patient-reported outcome (PRO) measure defined as longitudinal analysis of mean score over the first 5 treatment cycles. FKSI-10 patient responses for each question range from 0=not at all to 4=very much and after reverse coding the range of values for FKSI-10 total score is from 0 to 40; higher score represents better HRQOL." (NCT00073307)
Timeframe: From start of randomization of the first subject (1Dec2003) until the data cut-off (31May2005), approximately 18 months later, PRO data collected at Day 1 of each cycle and end of treatment.
| Intervention | Scores on a scale (Least Squares Mean) | ||||
|---|---|---|---|---|---|
| Cycle 2, Day 1 | Cycle 3, Day 1 | Cycle 4, Day 1 | Cycle 5, Day 1 | Cycles 1-5 (Overall) | |
| Placebo | 27.78 | 27.28 | 26.78 | 26.28 | 27.20 |
| Sorafenib (Nexavar, BAY43-9006) | 27.77 | 27.27 | 26.77 | 26.27 | 27.19 |
"Primary Analysis for FACT-G (using PWB score) patient-reported outcome (PRO) measure defined as longitudinal analysis of mean score over the first 5 treatment cycles. FACT-G (PWB score) patient responses for each question range from 0=not at all to 4=very much and after reverse coding the total FACT-G (PWB score) range of values is from 0 to 28; higher score represents better HRQOL." (NCT00073307)
Timeframe: From start of randomization of the first subject (1Dec2003) until the data cut-off (31May2005), approximately 18 months later, PRO data collected at Day 1 of each cycle and end of treatment.
| Intervention | Scores on a scale (Least Squares Mean) | ||||
|---|---|---|---|---|---|
| Cycle 2, Day 1 | Cycle 3, Day 1 | Cycle 4, Day 1 | Cycle 5, Day 1 | Cycles 1-5 (Overall) | |
| Placebo | 21.16 | 20.72 | 20.28 | 19.84 | 20.65 |
| Sorafenib (Nexavar, BAY43-9006) | 21.21 | 20.77 | 20.33 | 19.89 | 20.70 |
12 reviews available for niacinamide and Cardiovascular Diseases
| Article | Year |
|---|---|
Stemistry: the control of stem cells in situ using chemistry.
Topics: Animals; Antidepressive Agents; Bone Marrow Cells; Cardiovascular Diseases; Cell Differentiation; Ch | 2015 |
N1-methylnicotinamide as a possible modulator of cardiovascular risk markers in polycystic ovary syndrome.
Topics: Biomarkers; Cardiovascular Diseases; Female; Humans; Niacinamide; Polycystic Ovary Syndrome; Prodrom | 2019 |
Nicotinamide Riboside-The Current State of Research and Therapeutic Uses.
Topics: Aging; Animals; Betacoronavirus; Biological Availability; Cardiovascular Diseases; Coronavirus Infec | 2020 |
JAK inhibitors for the treatment of rheumatoid arthritis.
Topics: Adamantane; Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Benzofurans; Cardiovascular Dis | 2020 |
Risk of cardiovascular toxicities in patients with solid tumors treated with sorafenib: an updated systematic review and meta-analysis.
Topics: Antineoplastic Agents; Cardiotoxicity; Cardiovascular Diseases; Clinical Trials, Phase II as Topic; | 2014 |
Adverse effects of anticancer agents that target the VEGF pathway.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2009 |
Anti-vascular endothelial growth factor therapies and cardiovascular toxicity: what are the important clinical markers to target?
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineo | 2010 |
Cardiovascular safety of VEGF-targeting therapies: current evidence and handling strategies.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2010 |
Predicting and preventing cardiotoxicity in the era of breast cancer targeted therapies. Novel molecular tools for clinical issues.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2011 |
[New therapy strategies in secondary hyperparathyroidism on dialysis (I): new concepts, new treatments].
Topics: Algorithms; Bile Acids and Salts; Calcium; Cardiovascular Diseases; Disease Progression; Drug Therap | 2005 |
Pharmacology and structure-activity relationships for KATP modulators: tissue-selective KATP openers.
Topics: Action Potentials; Adenosine Triphosphate; Animals; Antihypertensive Agents; Benzopyrans; Cardiovasc | 1994 |
Potassium channel openers: pharmacological and clinical aspects.
Topics: Animals; Benzopyrans; Cardiovascular Diseases; Cromakalim; Heart; Humans; Muscle, Smooth; Nervous Sy | 1992 |
3 trials available for niacinamide and Cardiovascular Diseases
| Article | Year |
|---|---|
Effects of Adjuvant Sorafenib and Sunitinib on Cardiac Function in Renal Cell Carcinoma Patients without Overt Metastases: Results from ASSURE, ECOG 2805.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Cardiovascular Diseases; Chemotherapy, Ad | 2015 |
Efficacy and safety of sorafenib in patients with advanced renal cell carcinoma with and without prior cytokine therapy, a subanalysis of TARGET.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; | 2010 |
Hemodynamic effects of bolus nicorandil compared with nitroglycerin.
Topics: Aged; Cardiovascular Diseases; Emergencies; Female; Hemodynamics; Humans; Male; Middle Aged; Niacina | 1995 |
17 other studies available for niacinamide and Cardiovascular Diseases
| Article | Year |
|---|---|
Evaluation of cardiovascular events in patients with hepatocellular carcinoma treated with sorafenib in the clinical practice. The CARDIO-SOR study.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cardiovascular Diseases; Humans; Liver Neoplasms; | 2021 |
NAD+ metabolism and cardiometabolic health: the human evidence.
Topics: Cardiovascular Diseases; Humans; NAD; Niacinamide | 2021 |
Second line treatment of metastatic renal cell carcinoma: The Institut Gustave Roussy experience with targeted therapies in 251 consecutive patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antibodies, Monoclonal, Humanized; | 2013 |
Cardiovascular toxicity of multi-tyrosine kinase inhibitors in advanced solid tumors: a population-based observational study.
Topics: Adult; Aged, 80 and over; Canada; Cardiovascular Diseases; Female; Humans; Indoles; Male; Middle Age | 2015 |
Cardiovascular toxicity after antiangiogenic therapy in persons older than 65 years with advanced renal cell carcinoma.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Ca | 2016 |
Kidney cancer: TKIs associated with stroke risk.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Card | 2015 |
Niacin and Chronic Kidney Disease.
Topics: Biological Transport; Bone Diseases; Cardiovascular Diseases; Dyslipidemias; Humans; Hyperphosphatem | 2015 |
Tyrosine kinase inhibitors: can promising new therapy associated with cardiac toxicity strengthen the concept of teamwork?
Topics: Antineoplastic Agents; Benzenesulfonates; Cardiovascular Diseases; Humans; Indoles; Neoplasms; Niaci | 2008 |
Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma.
Topics: Aged; Aged, 80 and over; Benzenesulfonates; Biomarkers; Carcinoma, Renal Cell; Cardiovascular Diseas | 2008 |
[Recommendations for the management of Sorafenib in patients with hepatocellular carcinoma].
Topics: Administration, Oral; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cardiovas | 2010 |
Partial Response and Cardiovascular Recovery after Sorafenib Dose Reduction in a Multinodular HCC Patient.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cardiovascular Diseases; Dose-Response Relationshi | 2012 |
Cardiovascular comorbidities for prediction of progression-free survival in patients with metastatic renal cell carcinoma treated with sorafenib.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Cardiovascular Diseases; Comorbidity; Dis | 2012 |
[INPLACEN IN CARDIOVASCULAR THERAPY].
Topics: 17-Ketosteroids; Adrenal Cortex Hormones; Cardiovascular Diseases; Niacin; Niacinamide; Placental Ex | 1963 |
Increased cardiotoxicity of sorafenib in sunitinib-pretreated patients with metastatic renal cell carcinoma.
Topics: Aged; Atrial Fibrillation; Benzenesulfonates; Carcinoma, Renal Cell; Cardiovascular Diseases; Chest | 2007 |
[Basic directions in the study of the biochemistry of the myocardium].
Topics: Adaptation, Physiological; Animals; Camphor; Cardiac Glycosides; Cardiomegaly; Cardiovascular Diseas | 1967 |
[Therapeutic value of an association of phospholipids and adrenal cortex in hepatology].
Topics: Adolescent; Adrenal Cortex Hormones; Adrenal Glands; Adult; Aged; Asthenia; Biliary Tract Diseases; | 1971 |
[Use of an ATP-vitamin combination in geriatric patients].
Topics: Adenosine Triphosphate; Age Factors; Aged; Blood Glucose; Blood Proteins; Cardiovascular Diseases; C | 1972 |